Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single pediatric participant with SCN2A associated developmental epileptic encephalopathy